2AMGN : Amgen's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
Fierce Pharma4d
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What is William Blair’s Forecast for Amgen Q4 Earnings?
Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...
Behind the Scenes of Amgen's Latest Options Trends
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...
Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
Q1 Earnings Forecast for Amgen Issued By William Blair
Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...
Morningstar9d
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
Amgen discovers, develops ... Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion ...